Top Tweets for #METEx14
🔜 #ELCC26 @myESMO 🇩🇰
🔥Don’t miss the target: BRAF, HER2, METex14 and EGFR exon20 in focus
☑️ #BRAF #HER2 #METex14 #EGFRex20ins
🎙️Chair: Dr. Caicun Zhou, Dr. Natasha Leighl
@OncoAlert @Larvol #LCSM
Precision oncology keeps getting more precise 🔬✨
🚨Just published in @CCR_AACR our study: First-line MET TKIs vs immunotherapy ± chemotherapy in #METex14 #NSCLC
✦ ICI±chemo showed benefit in tumors with very high PD-L1
✦ MET TKIs extended survival in patients with lower PD-L1 or brain/bone involvement 🧠🦴
Grateful to have co-led this collaborative effort together with @LeXiuning w/ 💫 1st authors @pecci_federica1 & #HuiLi
💡 Moving beyond single biomarkers toward treatment strategies informed by the intersection of genomics and clinical context.
@OncoAlert @DanaFarber @DanaFarberNews @MDAndersonNews @
@Alfdoc2
Link: https://t.co/De7Mvyd8FU
🧬 Long-term data from the #VISION trial shows:
Tepotinib offers durable responses in METex14 skipping #NSCLC.
🔹 ORR: 51–57%
🔹 PFS: ~6–8.5 months
🔹 OS: ~20–22 months
🔹 Liquid biopsy effective for detection
#LungCancer #TargetedTherapy #METex14 #Tepotinib #Oncology
https://t.co/QjYhbnxfj7
@drgandara @n8pennell @DrSanjayPopat @NHSEngland 4/ @StephenVLiu on results from #METex14 cohort of CHRYSALIS: https://t.co/vOR19A5aox
Final results from #METex14 cohort of CHRYSALIS @JTOonline - amivantamab monotherapy in 97 pts with NSCLC and a MET exon 14 skip mutation. RR 32% with DOR 11.2m and PFS 5.3m. RR 50% as first-line; RR 19% if prior MET directed therapy given.
https://t.co/bE8htsFh4l
💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.
Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo
48% Asian, 39% white
9% discontinued due to side effects
@OncoAlert
Final results of #CHRYSALIS in #METex14 cohort (@JTOonline): Amivantamab in 97 METex14 NSCLC pts showed 32% ORR, DOR 11.2m, PFS 5.3m. ORR 50% in 1L, and 19% post-MET TKI. #LCSM #NSCLC @OncoAlert
https://t.co/w72wWHSR5b
Final results from #METex14 cohort of CHRYSALIS @JTOonline - amivantamab monotherapy in 97 pts with NSCLC and a MET exon 14 skip mutation. RR 32% with DOR 11.2m and PFS 5.3m. RR 50% as first-line; RR 19% if prior MET directed therapy given.
https://t.co/bE8htsFh4l
Liquid vs tissue biopsies for #METex14 in NSCLC from the VISION study of tepotinib @CCR_AACR from @ChristianRolfo et al. Those with positive liquid biopsy had higher tumor burden and detectable ctDNA burden associated with shorter PFS and OS.
https://t.co/uI300mCeuP
Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> https://t.co/6P7rEBX6hP
Panelists:
@ChristianRolfo
@UmbertoMalapel1
#YasushiYatabe
#MervatMahrous
Organizer:
@touchONCOLOGY
#TTLC25 "Best of Oral ABstracts" @BiagioRicciutMD @lungoncdoc
👉 Dr. Federica Pecci’s #METex14 NSCLC project
although no overall difference in PFS starting with either ICI or TKI, BUT:
(1) High PDL1 pts benefit more from first-line ICI more. (2) Low PDL1 and CNS mets pts benefit from first-line TKI (capmatinib tepotinib).
Real world data from Italy on #MET exon 14 mutations in NSCLC @ESMO_Open. In 146 pts with #METex14 NSCLC, 38% given capmatinib and 23% tepotinib. RR to MET inhibitors was 46% as 1L therapy, 33% in later lines. mPFS 6.6m, mOS 10.7m, intracranial RR 41%.
https://t.co/0pzaAsTZqe
Phase II Korean study of tepotinib in pts with tumors harboring #MET exon 14 mutations (mostly NSCLC) or MET amplification (NSCLC, gastric, H&N, GBM, others) @ESMO_Open. In #METex14, RR 52.2% and in MET amp, RR 70%. In METex14 NSCLC, PFS 9m, OS 17m.
https://t.co/OrtX0qs4IO
Today is World Lung Cancer Day
💡Idylla™ gets NSCLC patients their molecular biomarker results in only 3 hours! https://t.co/L9MLN48fFo
#Biocartis #Idylla #LungCancer #Lung #NSCLC #ALK #ROS1 #RET #METex14 #EGFR #BiomarkerTesting #WorldLungCancerDay #LungCancerAwareness #WLCD24
Helpful case report @ClinicalLung on use of tepotinib for #METex14 NSCLC in a pt with ESRD. Response without excess toxicity. PKs showed concentration post dialysis ~20% lower but all within range. Minimal renal excretion, high plasma protein binding.
https://t.co/1A3FVpnqSC
Dr. Yongchang Zhang at #ELCC24 presents phase IIIb study of savolitinib in NSCLC with #METex14. First-line use RR 62%, DCR 92%, mDOR 12.5m, mTTR 1.4m mPFS 13.7m. In previously treated, RR 39%, mDOR 11.1m, mPFS 11m. OS not reached. #ESMOAmbassadors @myESMO
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice
🔗https://t.co/vsdRT8iTc7
#METex14 #NSCLC
#TKIs #PreclinicalModel
@MarieNollet2
Last Seen Hashtags on Sotwe
mom son scene
Seen from Turkey
auxiouspanda #auxiouspanda #auxiouspanda filter:videos since:2026-09-20
Seen from Poland
KEEPING_THE_FIRE_ROCK
Seen from United States
wankchat
bixaa
Seen from United States
ddlg
Seen from United States
รับงานพนัส
Seen from Thailand
bacteriasprobioticas
Seen from United States
creepshot
Seen from United Kingdom
贡献女儿
Seen from Japan
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers